Immune-related adverse events (irAEs) seen in cancer patients treated with immune checkpoint inhibitors (ICI) range from common lower GI symptoms to rarer but potentially more serious toxicities such as myositis and pneumonitis. Given the spectrum of known side effects and the importance of staying on ICI treatment where possible, ASCO has developed a set of ...
New ASCO recommendations on management of irAEs
By Mardi Chapman
11 Nov 2021